Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian markets drift lower
Wed, 16 Apr 01:30 pm

In the post noon session, the Indian indices have drifted into the red. There is broad based selling on the bourses. Apart from the FMCG index all other sectoral indices are trading below the dotted line.

The BSE-Sensex is trading down 170 points and the NSE-Nifty is trading down 52 points. The BSE Mid Cap index is trading down 1.1% and the BSE Small Cap index is trading down 0.9%. The rupee is trading at 60.26 to the US dollar.

Most of the domestic pharma stocks are trading in the red with Orchid Chemicals and Dishman Pharma being the biggest losers whereas Panacea Biotech and Piramal Enterprises are among the few stocks trading in the green. As per a leading financial daily, Cadila Healthcare and its US-based subsidiary Zydus Pharmaceuticals have entered into agreement with Depomed Inc. for the settlement of a patent infringement litigation. The ongoing litigation is related to a neuropathic drug Gralsie (gabapentin) tablets in 300 mg and 600 mg strengths. As per the settlement reached, Cadila and Zydus have secured permits to sell the generic versions of Gralise on January 1st 2024 or earlier subject to certain circumstances. Reportedly, Depomed clocked sales of $36.2 m in 2013 for Gralise. Cadila and Zydus Pharmaceuticals had settled a patent dispute related to Asacol delayed-release tablets in December 2013. Cadila Healthcare stock is presently trading up marginally.

Telecom stocks are trading lower today. Mahanagar Telephone Nigam Ltd (MTNL) and Tata Teleservices are leading the losses. India's newest telecom firm Reliance Jio Infocomm has signed its third infrastructure sharing agreement with Reliance Communications. The agreement will allow the company to use Reliance Communication's pan-India inter-city fiber optic network. This will enable a faster roll out of its 4G services across the country. The company has planned the roll out in September this year. The agreement is based on arm's length pricing at prevailing market rates. RCOM has about 500,000 Kms of fiber-optic cable network connecting over 300 cities in India. The earlier two agreements between the two companies were signed in April and August last year.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian markets drift lower". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.